DE60030173D1 - Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten - Google Patents

Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten

Info

Publication number
DE60030173D1
DE60030173D1 DE60030173T DE60030173T DE60030173D1 DE 60030173 D1 DE60030173 D1 DE 60030173D1 DE 60030173 T DE60030173 T DE 60030173T DE 60030173 T DE60030173 T DE 60030173T DE 60030173 D1 DE60030173 D1 DE 60030173D1
Authority
DE
Germany
Prior art keywords
treatment
mbl
mannan
prophylaxis
binding lectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60030173T
Other languages
English (en)
Other versions
DE60030173T2 (de
Inventor
Steffen Thiel
Jens Christian Jensenius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60030173D1 publication Critical patent/DE60030173D1/de
Publication of DE60030173T2 publication Critical patent/DE60030173T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
DE60030173T 1999-05-14 2000-05-10 Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten Expired - Fee Related DE60030173T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DK66899 1999-05-14
DKPA199901508 1999-10-20
DK150899 1999-10-20

Publications (2)

Publication Number Publication Date
DE60030173D1 true DE60030173D1 (de) 2006-09-28
DE60030173T2 DE60030173T2 (de) 2007-08-23

Family

ID=26064419

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60033147T Expired - Fee Related DE60033147T2 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin
DE60030173T Expired - Fee Related DE60030173T2 (de) 1999-05-14 2000-05-10 Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
DE60009896T Expired - Fee Related DE60009896T2 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60033147T Expired - Fee Related DE60033147T2 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60009896T Expired - Fee Related DE60009896T2 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Country Status (15)

Country Link
US (5) US6562784B1 (de)
EP (3) EP1402897B1 (de)
JP (2) JP2002543837A (de)
CN (2) CN1359298A (de)
AT (3) ATE264111T1 (de)
AU (2) AU779404B2 (de)
CA (2) CA2372128A1 (de)
DE (3) DE60033147T2 (de)
DK (3) DK1181038T3 (de)
ES (3) ES2219336T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515718A (de)
PT (3) PT1181363E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000070043A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
ES2219336T3 (es) * 1999-05-14 2004-12-01 Steffen Thiel Nuevas indicaciones de lectina de union a manano (mbl) en el tratamiento de individuos inmunocomprometidos.
US7387993B2 (en) * 2000-07-13 2008-06-17 Natimmune A/S Mannan-binding lectin (MBL) treatment of infections in individuals treated with TNF-αinhibitors
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
EP1349573A1 (de) * 2000-11-27 2003-10-08 Jens Christian Jensenius Collectine als adjuvantien
JP2005506967A (ja) 2001-07-23 2005-03-10 ナティミューン アクティーゼルスカブ 高分子質量レクチンの生産
WO2003018617A1 (fr) * 2001-08-31 2003-03-06 Fuso Pharmaceutical Industries, Ltd. Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain
ATE311400T1 (de) * 2001-10-19 2005-12-15 Natimmune As Isolierung von lectinen
PT1344533E (pt) * 2002-03-15 2007-01-31 Natimmune As Composições farmacêuticas compreendendo lectina de ligação a manose
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
NZ535600A (en) * 2002-04-24 2008-03-28 Queensland Inst Med Res MASP-depleted MBL compositions are superior at activating the complement cascade when compared with MBL purified in complex with its associated MASPs
JPWO2004002511A1 (ja) * 2002-06-28 2005-10-27 扶桑薬品工業株式会社 抗ｈｉｖ剤
AU2003260286A1 (en) * 2002-09-10 2004-04-30 Natlmmune A/S Collectin-complement activating protein chimeras
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
CA2516403C (en) 2003-01-17 2014-08-12 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
SI1625166T1 (sl) 2003-05-12 2015-08-31 Helion Biotech Aps Protitelesa masp-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1721004A2 (de) * 2004-02-24 2006-11-15 Innogenetics N.V. Verfahren zur bestimmung des risikos einer neurologischen krankheit
AU2005222381B2 (en) * 2004-03-09 2010-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVL, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
EP1797197A1 (de) * 2004-09-29 2007-06-20 Mellitus S.L. Verfahren zur detektion einer prädisposition für schwangerschaftsdiabetes sowie zur behandlung dieser krankheit
ATE499945T1 (de) * 2004-12-23 2011-03-15 Council Scient Ind Res Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
EP1830810A4 (de) * 2004-12-30 2011-02-02 Dobeel Co Ltd Sprühgetrocknete zusammensetzung mit proteinen der collectin-familie oder varianten davon und herstellungsverfahren dafür
EP1874333A2 (de) * 2005-04-11 2008-01-09 Natimmune A/S Mannan-bindungslectin (mbl) bei der behandlung von immunschwäche im zusammenhang mit krebs
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
EP1965831B1 (de) 2005-12-21 2011-07-13 Pharming Intellectual Property B.V. Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
EP2247846B1 (de) * 2008-01-16 2012-11-28 Superpar Otomotiv San. Ve Tic. A.S. Elektrische kraftstoffpumpe für hdep (heavy duty engine platforms - schwere motorenplattformen)
WO2009126346A2 (en) * 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
AU2011207626B2 (en) 2010-01-19 2015-06-18 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
WO2011100528A2 (en) 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
SG10201608671SA (en) 2011-07-18 2016-12-29 Harvard College Engineered Microbe-Targeting Molecules and Uses Thereof
EP2820147B1 (de) 2012-02-29 2018-08-08 President and Fellows of Harvard College Schnelltests auf empfindlichkeit gegen antibiotika
EP3327090A1 (de) 2012-07-18 2018-05-30 President and Fellows of Harvard College Modifizierung von oberflächen zur gleichzeitigen abweisung und gezielten bindung gewünschter gruppen
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
CA2913155A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
CN109476764A (zh) 2016-05-16 2019-03-15 哈佛大学校长及研究员协会 偶联在经co2-等离子体活化的表面上的水性生物分子
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856180T2 (de) * 1987-08-20 1998-09-03 Childrens Medical Center Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
CA2400143C (en) 1995-08-17 2009-05-12 Fuso Pharmaceutical Industries, Ltd. Recombinant conglutinin and producing method thereof
CN1106846C (zh) 1997-08-21 2003-04-30 宝酒造株式会社 抗癌症剂
ES2272067T3 (es) * 1998-06-10 2007-04-16 Statens Serum Institut Procedimiento de purificacion para la produccion de lecitina de union a manano y un producto medicinal de mbl.
ES2219336T3 (es) * 1999-05-14 2004-12-01 Steffen Thiel Nuevas indicaciones de lectina de union a manano (mbl) en el tratamiento de individuos inmunocomprometidos.

Also Published As

Publication number Publication date
AU781135B2 (en) 2005-05-05
DE60009896D1 (de) 2004-05-19
EP1181363A1 (de) 2002-02-27
DE60033147D1 (de) 2007-03-15
US6846649B1 (en) 2005-01-25
DE60030173T2 (de) 2007-08-23
ATE352620T1 (de) 2007-02-15
ATE264111T1 (de) 2004-04-15
NO20015481L (no) 2002-01-11
PT1181363E (pt) 2007-05-31
JP2002543837A (ja) 2002-12-24
CN1359298A (zh) 2002-07-17
NO20015506D0 (no) 2001-11-09
EP1402897A2 (de) 2004-03-31
WO2000070043A1 (en) 2000-11-23
RU2292217C2 (ru) 2007-01-27
DK1402897T3 (da) 2006-12-27
WO2000069894A2 (en) 2000-11-23
ES2281341T3 (es) 2007-10-01
JP2002544286A (ja) 2002-12-24
AU4393500A (en) 2000-12-05
ES2271468T3 (es) 2007-04-16
NO20015506L (no) 2002-01-09
DE60033147T2 (de) 2007-12-13
EP1402897B1 (de) 2006-08-16
AU4393600A (en) 2000-12-05
US20040229212A1 (en) 2004-11-18
AU779404B2 (en) 2005-01-20
US20030191052A1 (en) 2003-10-09
DE60009896T2 (de) 2005-04-21
EP1181363B1 (de) 2007-01-24
EP1181038B1 (de) 2004-04-14
NZ515718A (en) 2004-03-26
WO2000069894A3 (en) 2001-02-08
PT1181038E (pt) 2004-08-31
DK1181038T3 (da) 2004-08-09
NZ515717A (en) 2004-01-30
NO20015481D0 (no) 2001-11-08
US7202207B2 (en) 2007-04-10
RU2005125625A (ru) 2007-02-20
EP1402897A3 (de) 2004-06-30
ATE336260T1 (de) 2006-09-15
PT1402897E (pt) 2007-01-31
CN1359420A (zh) 2002-07-17
EP1181038A2 (de) 2002-02-27
US6562784B1 (en) 2003-05-13
US20070197428A1 (en) 2007-08-23
CA2372435A1 (en) 2000-11-23
CA2372128A1 (en) 2000-11-23
US7439224B2 (en) 2008-10-21
DK1181363T3 (da) 2007-05-29
ES2219336T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
DE60009896T2 (de) Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
EP2769715A3 (de) Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
MY106315A (en) Pharmaceutical agents
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
BG105302A (en) Means for improving cognition
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
PT652900E (pt) Inibidores da trombina
DE59900222D1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE262343T1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee